// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Effectiveness of icatibant to control symptoms of HAE attacks in real‐world clinical practice

Caballero T - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Icatibant

Treatment of acute attacks of hereditary angioedema due to C1 inhibitor deficiency with icatibant in paediatric versus adult patients: Findings from the icatibant outcome survey

Longhurst H. J - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

C1 Inhibitor Deficiency

Icatibant

Long‐term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX‐S study

Reshef A - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary angioedema

BCX7353

DE‐labelling beta‐lactam allergy using telemedicine and single dose oral challenge in a low risk paediatric cohort: Outcome of DE‐labelling process one year later

Allen HI - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

C1 Inhibitor Deficiency

N/A

Has NAP 6 caught us napping?: Anaesthetist's perspective for drug hypersensitivity reactions

Romero P - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis

Gevaert P - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Omalizumab

Peanut allergy impact on productivity and quality of life (PAPRIQUA): The psychosocial impact of peanut allergy in children and caregivers

Acaster S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Intravenous fluids are effective for managing cardiovascular changes and gastrointestinal symptoms during food‐related anaphylaxis

Ruiz-Garcia M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anaphylaxis

Cheetah Suspension

PIPE‐cloned human IgG4 antibodies inhibit activation of human basophils sensitized with IgE antibodies specific for the major milk allergen beta‐lactoglobulin in basophil activation tests (BAT)

Pranger CL - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

IL-4

Predictors of food sensitisation in European children and adults

Lyons SA - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of structural stability on endolysosomal degradation and T‐cell reactivity of the invertebrate pan‐allergen, tropomyosin

Kamath SD - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adult‐onset cow's milk allergy: New challenges with atypical presentations

Pur Ozyigit L - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PALISADE follow‐on study (ARC004): Longer‐term outcomes with AR101 oral immunotherapy for peanut allergy

Fernndez-Rivas M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

South Asian mothers’ views and experiences of accessing paediatric allergy services in sheffield for their babies and/or young children

Peckover S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Asthma

N/A

A case controlled retrospective study on the effect of neonatal probiotic supplementation on the incidence and tolerance to Cow's Milk Protein Allergy

Lloyd E - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Relationship between house dust mites sensitization profiles and type and severity of respiratory allergic diseases in children

Umanets T - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Recognition and treatment of paediatric anaphylaxis: Would you know what to do?

Halton FF - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anaphylaxis

N/A

Diagnosing asthma in adults– prospective testing of the UK national guideline

Drake S - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone

Diagnosing asthma in children – prospective testing of the UK national guideline

Murray C - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone

The correlation between outcomes of “supervised feeds” and immunological cut‐off values in food allergic children

Krishnan M - European Academy of Allergy and Clinical Immunology (EAACI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved